Immunotherapy: Breakthroughs in Treatment
This activity consists of recorded presentations from the "30th Annual National Conference" held virtually Sept. 29–30, 2021.
Cellular immunotherapy encompasses a broad range of cancer treatments that engage different aspects of the patient’s own immune system: adoptive cell therapy, cancer vaccines, immunomodulators, oncolytic virus therapy and targeted antibodies. Current research is focused on predicting responses, suppressing immune responses to cancer cells, reducing side effects and finding solutions for treatment resistance. The recent breakthrough of CAR T-cell immunotherapy, named “the 2018 advance of the year” by ASCO, is making once-untreatable cancers now treatable through the genetic reprogramming of immune cells to specifically locate and attack cancer cells throughout the body. What does CAR T-cell therapy entail? For which patients and cancer types has it been shown to be effective? Learn about recent advances in the field of immunotherapy, examine the ongoing developments in CAR T-cell therapy, and discuss its safety, advantages, concerns, and clinical trials.
This activity is provided by OptumHealth Education.
There was no commercial support for this activity.
Please ensure you are using the web-browser Chrome and disable any pop-up blocking software. Click here for information on how to enable pop-ups.
This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians, psychologists, social workers and other health care professionals who are interested in immunotherapy treatments.
At the end of this educational activity, participants should be able to:
- Explore current immunotherapies, including the basics of their mechanisms of action, indications and effectiveness.
- Describe the issues that immunotherapy research seeks to address in providing more-effective cancer treatments.
- Review aspects of CAR T-cell therapy, including recent clinical trials, effectiveness, safety, advantages and concerns.
- Discuss the future direction of immune cell and CAR T-cell therapies for cancer treatments.
Robert L. Ferris, MD, PhD
Associate Vice-Chancellor for Cancer Research
Hillman Professor of Oncology
University Pittsburgh School of Medicine;
UPMC Hillman Cancer Institute
Elizabeth Albert, MD
Clinical Activity Manager
Eden Prairie, MN
Matthew Cooper, MD
President Elect, UNOS
Director, Kidney and Pancreas Transplantation
Medical Director, Transplant QAPI
Medstar Georgetown Transplant Institute;
Professor of Surgery
Georgetown University School of Medicine
Rebecca Gleason, RN, CCM
Clinical Activity Manager
Eden Prairie, MN
Alan N. Langnas, DO, FACS
Professor of Surgery
Director, Center of Transplantation
Chief, Section of Transplantation,
Department of Surgery
University of Nebraska Medical Center;
Director of Liver Transplantation
C. Fred LeMaistre, MD
Senior Vice President, Market Operations
Tina Rydland, PharmD
Crystal Wong, MD
Propoint Medical Writing
Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, OptumHealth Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.
Dr. Ferris has indicated that he is on an advisory board for Achilles Therapeutics, EMD Serono, Instil Bio, Inc., Lifescience Dynamics Limited, MacroGenics, Inc., Numab Therapeutics AG, OncoCyte Corporation, Pfizer, Rakuten Medical, Inc., and Seagen, Inc.; receives clinical trial support from Merck, is on an advisory board, receives clinical trial support and grant/research support funding from Bristol Myers Squibb; receives clinical trial and grant/research support from AstraZeneca and Medlmmune; is a consultant for Aduro Biotech, Inc., Bicara Therapeutics, Inc., Everest Clinical Research Corporation, F. Hoffmann-La Roche Ltd, Genocea Biosciences, Inc., Kawa Research Institute, Inc., Mirati Therapeutics, Inc., Nanobiotix, PPD, Sanofi, and Zymeworks, Inc.; is a consultant for, holds stock/ownership interest in and receives grant/research funding from Novasenta; and receives grant support from Tesaro.
The activity planners have no financial relationships to disclose.
Method for calculating CE credit
CE credit was calculated by the complexity of content.
In support of improving patient care, OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation Statements
The participant will be awarded up to 1.0 contact hour(s) of credit for attendance and completion of supplemental materials.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
This activity is approved for 1.0 contact hour(s) ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.0 contact hour(s).
Unique Activity Number(s): JA0007123-0000-21-275-04-P/T
OptumHealth Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
The Commission for Case Manager Certification has approved this program for a maximum of 1.0 clock hour(s) for Certified Case Managers (CCM).
Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit=One CPEU).
If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (One 60 minute hour=1 CPEU).
RD's and DTRs are to select activity type 102 in their Activity Log. Performance indicator selection is at the learner's discretion.
Psychologists and social workers
Participants must have attended the entire Web-based activity and completed an evaluation to receive a certificate. Partial credit is not available.
OptumHealth Education is approved by the American Psychological Association (APA) to offer continuing education for psychologists. OptumHealth Education maintains responsibility for this program. 1.0 CE hour.
As a Jointly Accredited Organization, OptumHealth Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. OptumHealth Education maintains responsibility for this course. Social workers completing this course receive 1.0 enduring continuing education credit.
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization with which they wish to obtain credit.
- 1.00 ACPE - Pharmacist
- 1.00 ACPE - Pharmacy Technician
- 1.00 AMA
- 1.00 ANCC
- 1.00 APA
- 1.00 Attendance
- 1.00 CCMC - General
- 1.00 CDR
Prior to beginning this activity, please ensure you are using the web-browser Chrome and disable any pop-up blocking software. Click here for information on how to enable pop-ups.
You must be logged into your account to participate in this activity. Get started by clicking “Continue” and taking the “Pre-Activity Assessment”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. A complete listing of all of your activities can be found under “My Account”, “My Activities.”